

EMA/139205/2016 corr

European Medicines Agency decision

P/0080/2016

of 18 March 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for exenatide (EMEA-001755-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0080/2016

of 18 March 2016

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for exenatide (EMA-001755-PIP01-15) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Les Laboratoires Servier on 16 March 2015 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2016, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for exenatide, implant, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for exenatide, implant, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for exenatide, implant, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Les Laboratoires Servier, 50, rue Carnot, 92284 – Suresnes, France.

Done at London, 18 March 2016

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/761332/2015

London, 29 January 2016

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001755-PIP01-15

Scope of the application

Active substance(s):

Exenatide

Condition(s):

Treatment of type 2 diabetes mellitus

Pharmaceutical form(s):

Implant

Route(s) of administration:

Subcutaneous use

Name / corporate name of the PIP applicant:

Les Laboratoires Servier

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Les Laboratoires Servier submitted for agreement to the European Medicines Agency on 16 March 2015 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 21 April 2015.

Supplementary information was provided by the applicant on 6 November 2015.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of type 2 diabetes mellitus

The waiver applies to:

- the paediatric population from birth to less than 10 years;
- implant, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of type 2 diabetes mellitus

2.1.1. Indication(s) targeted by the PIP

Treatment of type 2 diabetes mellitus

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 10 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Implant

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	2	Study 1 • <i>Preliminary juvenile animal toxicity</i> study for selection of the doses of continuous subcutaneous (CS) exenatide to be used in the definitive juvenile toxicity study. Study 2 • <i>Definitive juvenile toxicity study</i> to assess the potential for acceleration of sexual development linked to CS exenatide administration.

Clinical studies	2	Study 3 Pharmacokinetic (PK) study in paediatric patients aged 10 to less than 18 years, with type 2 diabetes mellitus (T2D) on stable treatment regimen of diet and exercise in combination with metformin. Study 4 Double-blind, placebo-controlled efficacy and safety study of CS exenatide in paediatric patients aged 10 to less than 18 years, with T2D on stable treatment regimen of diet and exercise in combination with metformin.
Extrapolation, modelling and simulation studies	2	Study 5 Population pharmacokinetic study to evaluate the CS exenatide pharmacokinetic characteristics in paediatric patients aged 10 to less than 18 years, with T2D. Study 6 Modelling and simulation study to evaluate the exenatide CS pharmacokinetic characteristics and the pharmacokinetic/pharmacodynamic (PK/PD) relationship in paediatric patients aged 10 to less than 18 years, with T2D.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By March 2028.
Deferral for one or more measures contained in the paediatric investigation plan:	Yes